Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2021

Genmab — December 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • S Offline
    S Offline
    Sukkeralf
    wrote on sidst redigeret af
    #100

    Just a moment...

    favicon

    (firstwordpharma.com)

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #101

      Hvad handler det om sukkeralf?

      1 Reply Last reply
      0
      • Legolas23L Offline
        Legolas23L Offline
        Legolas23
        wrote on sidst redigeret af
        #102

        Kan du sætte lidt prosa. Linket kræver medlemskab.

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #103

          God morgen. 🙂

          1 Reply Last reply
          0
          • G Offline
            G Offline
            GeorgeBest
            wrote on sidst redigeret af
            #104

            Denne onkolog undrer sig over hvorfor man overhovedet vil anvende CAR-T i MM, når man snart kan få Teclistamab som vil være „safer, better, easier and cheaper“ https://twitter.com/drpaulydesantis/status/1466262720127258625?s=21

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #105

              Detailed results from Roche's POLARIX study are poised to be one of the highlights at next week's annual meeting of the American Society of Hematology (ASH).

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #106

                Roche notes that POLARIX is the first positive DLBCL Phase III study in a curative setting for two decades. Furthermore, it has suggested that sales of Polivy could peak at around $2 billion if the antibody-drug conjugate (ADC) becomes established as a new standard of care in the first-line setting.

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #107

                  In response to publication of the abstract, we snap-polled 43 oncologists, 56% of whom said the Polivy-based regimen looks superior to current standard of care based on PFS data alone.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #108

                    35% says acceptable adverse effect profile and 51% says manageable

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #109

                      Taking efficacy and safety into account, results from POLARIX were described by 44% of oncologists as clinically meaningful and by a further 40% as promising, suggestive that physicians still want to see further detailed results and ideally a survival benefit (despite DLBLC being a relatively slowly progressing disease).

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #110

                        And then they want to see OS data

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #111

                          Regarding Genmabs DuoBody agreement with Janssen we maybe could get an idea of how backloaded the deal is by looking at Zymeworks deal with Janssen.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #112

                            For 6 programs Zymeworks got 50 million dollars upfront and are eligible for up to $282M in development milestone payments as well as $1.12B in commercial milestones. Thats about 233 milliion dollars pr program which is bit more than Genmabs deal but also 5 years later. So kind of the same I guess.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #113

                              So that means around 20% of the milestone are development and 80% commercial - so quite backloaded I must say

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #114

                                Zymeworks also get single mid digit royalty

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  svak
                                  wrote on sidst redigeret af
                                  #115

                                  ser ikke ud til at godkendelsen hos FDA på dara kyprolis skal give noget - positivt ja - og fald som standard

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #116

                                    NBI faldt en del i går aftes

                                    1 Reply Last reply
                                    0
                                    • StockBullS Offline
                                      StockBullS Offline
                                      StockBull
                                      wrote on sidst redigeret af
                                      #117

                                      DAGKORT: Trendkanalen stadig intakt. RSI indikere oversolgt så krydret med lidt godt nyt bør kursen snart rykke opad. MACD kan ses mindre lyserøde stage fra dag til dag så det tyder på vi snart skal til at se de foretrukne grønne lys. https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/99079_Skaermbillede_2021_12_02_150642_genmabbb.jpg

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #118

                                        @GB 5:48: Det er jo det vi har sagt hele tiden 😉

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          GeorgeBest
                                          wrote on sidst redigeret af
                                          #119

                                          Rigtigt Bulder, men også rart at eksperterne mener det samme 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper